FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 180 filers reported holding FATE THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 1.39 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $40,704 | -97.1% | 19,200 | -86.2% | 0.00% | -100.0% |
| Q4 2022 | $1,402,510 | -26.2% | 139,000 | +63.8% | 0.01% | -25.0% |
| Q3 2022 | $1,901,000 | -23.7% | 84,856 | -15.6% | 0.02% | -33.3% |
| Q2 2022 | $2,493,000 | +564.8% | 100,592 | +2343.3% | 0.02% | +380.0% |
| Q4 2020 | $375,000 | +3.0% | 4,117 | -54.8% | 0.01% | -28.6% |
| Q3 2020 | $364,000 | -75.7% | 9,113 | -90.5% | 0.01% | -84.1% |
| Q3 2019 | $1,496,000 | +547.6% | 96,400 | +748.2% | 0.04% | +450.0% |
| Q2 2019 | $231,000 | -87.8% | 11,365 | -90.2% | 0.01% | -90.5% |
| Q3 2018 | $1,891,000 | – | 116,100 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $200,277,000 | 17.57% |
| Redmile Group, LLC | 12,957,222 | $767,975,000 | 13.39% |
| Copernicus Capital Management, LLC | 12,000 | $711,000 | 8.60% |
| Grosvenor Holdings, L.L.C. | 1,037,256 | $61,478,000 | 7.53% |
| DAFNA Capital Management LLC | 344,360 | $20,410,000 | 5.42% |
| Casdin Capital, LLC | 3,400,000 | $201,518,000 | 5.02% |
| Ally Bridge Group (NY) LLC | 270,000 | $16,003,000 | 4.70% |
| Darwin Global Management, Ltd. | 353,250 | $20,937,000 | 3.85% |
| Bellevue Group AG | 3,238,036 | $191,918,000 | 1.95% |
| Artal Group S.A. | 1,450,000 | $85,942,000 | 1.92% |